Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21936057 | 0.87 | MAPT (0.46) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL22519135 | 0.87 | NPC1 (0.56) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL21936036 | 0.86 | PTGS1 (0.44) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL31528481 | 0.86 | RAB9A (0.52) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL24616739 | 0.85 | PDE4A (0.47) | PTGS1PTGS2NPC1RAB9ATARBP2 | |
| SCHEMBL21937178 | 0.82 | PTGS1 (0.42) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL20876131 | 0.81 | PTGS1 (0.41) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL20876163 | 0.81 | PTGS1 (0.41) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL18131809 | 0.81 | PTGS1 (0.44) | PTGS1PTGS2NPC1RAB9AMAPT | |
| SCHEMBL23387882 | 0.80 | PTGS1 (0.65) | PTGS1PTGS2RAB9APDE4AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50663-E1 | Heterocycle derivatives as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2025-11-18 | — | — | US | disclosed |
| CN-111433215-B | Derivatives of heterocyclic compounds as pest control agents | 拜耳公司 | 2023-10-03 | — | — | CN | disclosed |
| US-10981935-B2 | Heterocycle derivatives as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200291043-A1 | HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | disclosed |
| EP-3692045-A1 | DERIVATIVES OF HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | Bayer Aktiengesellschaft (DE) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019068572-A1 | DERIVATIVES OF HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291043-A1 | HETEROCYCLE DERIVATIVES AS PESTICIDES | DDT, CBR3, CBR1 | PTGS1 2790/4885PTGS2 2875/4885NPC1 4017/4885 |
| US-10981935-B2 | Heterocycle derivatives as pesticides | DDT, CBR3, CBR1 | PTGS1 2790/4885PTGS2 2875/4885NPC1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.